Immediate Impact
68 standout
Citing Papers
Strategic advancements in targeting the PI3K/AKT/mTOR pathway for Breast cancer therapy
2025 Standout
Cancer stem cells and niches: challenges in immunotherapy resistance
2025 Standout
Works of S. Morris being referenced
Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I/III trial
2020
3 Afuresertib (GSK2110183), an oral AKT kinase inhibitor, in combination with carboplatin and paclitaxel in recurrent ovarian cancer
2014
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| S. Morris | 233 | 119 | 51 | 89 | 13 | 257 | |
| M. Reck | 245 | 206 | 74 | 44 | 18 | 306 | |
| J.-S. Lee | 258 | 192 | 66 | 42 | 17 | 297 | |
| Moises J. Velez | 220 | 106 | 79 | 87 | 14 | 291 | |
| Xiaobin Zheng | 201 | 97 | 49 | 82 | 14 | 273 | |
| Giuliano Palumbo | 150 | 88 | 78 | 70 | 15 | 221 | |
| Elisabetta Gambale | 169 | 112 | 45 | 20 | 19 | 236 | |
| V. Westeel | 253 | 191 | 84 | 109 | 20 | 314 | |
| Xue‐Wu Wei | 167 | 160 | 62 | 24 | 13 | 258 | |
| Jiewen Peng | 205 | 100 | 52 | 73 | 18 | 327 | |
| Atsuko Umezawa | 180 | 106 | 96 | 124 | 12 | 316 |
All Works
Loading papers...